Table 1.
Patient comorbidities and demographic data
| All patients (n=199) | DVT (n=12) | non-DVT (n=187) | p | |
|---|---|---|---|---|
| Age (years) (mean±SD) | 65.56±10.81 | 70.42±9.99 | 65.25±10.81 | 0.13 |
| Gender | 0.18 | |||
| Male, n (%) | 104 (52.26) | 4 (3.85) | 100 (96.15) | |
| Female, n (%) | 95 (47.74) | 8 (8.42) | 87 (91.58) | |
| BMI (kg/m2) | 27.35 ± 4.6 | 28.08±3.92 | 27.31±4.65 | 0.54 |
| SHT, n (%) | 147 (73.87) | 8 (66.66) | 139 (74.33) | 0.81 |
| CCD, n (%) | 76 (38.19) | 4 (33.33) | 72 (38.50) | 0.86 |
| AFib, n (%) | 9 (4.52) | 1 (8.33) | 8 (4.27) | 0.99 |
| Smoker, n (%) | 6 (3.02) | 1 (8.33) | 5 (2.67) | 0.76 |
| CHF, n (%) | 11 (5.52) | 0 (0) | 11 (5.88) | 0.99 |
| Dyslipidemia, n (%) | 8 (4.02) | 1 (8.33) | 6 (3.21) | 0.35 |
| T2DM, n (%) | 21 (10.55) | 2 (16.66) | 19 (10.16) | 0.74 |
| Obesity, n (%) | 11 (5.53) | 3 (25) | 8 (4.27) | 0.54 |
| Malignancy, n (%) | 8 (4.02) | 0 (0) | 8 (4.27) | 0.99 |
| CKD, n (%) | 2 (1) | 0 (0) | 2 (1.07) | 0.99 |
| Varicose veins, n (%) | 14 (7.04) | 1 (8.33) | 13 (6.95) | 0.79 |
Table 2.
Laboratory parameters of the patients
| Parameter median (Q1-Q3) | All patients (n=199) | DVT (n=12) | non-DVT (n=187) | p |
|---|---|---|---|---|
| Hb (g/dL) | 13.8 (12.83–14.77) | 13.71 (12.53 – 14.45) | 13.8 (12.8 – 14.8) | 0.42 |
| Hct (%) | 41.7 (39.13–44.4) | 41.06 (37.23–42.26) | 41.8 (39.25 – 44.42) | 0.28 |
| Neu (×103/µL) | 4.84 (3.7–5.98) | 4.47 (4.12–6.26) | 4.85 (3.69–5.98) | 0.66 |
| Ly (×103/µL) | 1.97 (1.51–2.55) | 1.56 (1.09–2.44) | 1.98 (1.55–2.55) | 0.18 |
| Mo (×103/µL) | 0.51 (0.41–0.68) | 0.47 (0.3–0.64) | 0.51 (0.41–0.68) | 0.60 |
| Tr (×103/µL) | 246 (207.5–291.4) | 210.1 (178.5–284.25) | 246.4 (211.55–291.4) | 0.23 |
| MLR | 0.27 (0.2–0.37) | 0.36 (0.22–0.53) | 0.27 (0.2–0.36) | 0.12 |
| NLR | 2.45 (1.79–3.19) | 3.16 (1.7–5.52) | 2.42 (1.81–3.13) | 0.27 |
| PLR | 124.05 (96.96–164.48) | 163.39 (114.32–175.73) | 123.01 (96.96–162.51) | 0.27 |
| SII | 572.52 (429.22–846.22) | 660.26 (489.95–1100.5) | 568.52 (429.22–823.18) | 0.33 |
| SIRI | 65.26 (49.05 – 85.63) | 67.5 (40.62–94.85) | 65.26 (49.73–85.31) | 0.89 |
| AISI | 290.48 (199.83–480.87) | 302.35 (182.43–761.33) | 290.48 (204.22–477.56) | 0.85 |
| Glycemia (mg/dL) | 102 (92–115) | 106.49 (83.5–115.75) | 102 (92–115) | 0.81 |
| APTT (seconds) | 25.85 (23.9–28.13) | 27.45 (27.05–31) | 25.8 (23.9–28.1) | 0.09 |
| INR | 0.98 (0.93–1.08) | 1 (0.96–1.06) | 0.98 (0.93–1.08) | 0.61 |
| Serum urea (mg/dL) | 34.8 (28.35–42.9) | 29 (21.88–38.13) | 35.3 (28.8–42.9) | 0.13 |
| Serum Creatinine (mg/dL) | 0.8 (0.72–0.94) | 0.93 (0.62–1.03) | 0.8 (0.73–0.94) | 0.60 |
| LOS (days) | 7 (6–10) | 9 (7.75–11.25) | 7 (6–10) | 0.38 |
| Death (number) | 3 | 3 | 0 | <0.001 |
[i] Hb, haemoglobin; Hct, haematocrit; Neu, neutrophil count; Ly, lymphocyte count; Mo, monocyte count; Tr, thrombocyte counts; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelets-to-lymphocyte ratio; SII, systemic inflammatory index; SIRI, systemic inflammation response index (SIRI); AISI, aggregate index of systemic inflammation; APTT, activated partial thromboplastin time; INR, international normalised ratio; LOS, length of hospital stay;